| Literature DB >> 22634634 |
Stefanie Blättermann1, Lucas Peters, Philipp Aaron Ottersbach, Andreas Bock, Viktoria Konya, C David Weaver, Angel Gonzalez, Ralf Schröder, Rahul Tyagi, Petra Luschnig, Jürgen Gäb, Stephanie Hennen, Trond Ulven, Leonardo Pardo, Klaus Mohr, Michael Gütschow, Akos Heinemann, Evi Kostenis.
Abstract
Differential targeting of heterotrimeric G protein versus β-arrestin signaling are emerging concepts in G protein-coupled receptor (GPCR) research and drug discovery, and biased engagement by GPCR ligands of either β-arrestin or G protein pathways has been disclosed. Herein we report on a new mechanism of ligand bias to titrate the signaling specificity of a cell-surface GPCR. Using a combination of biomolecular and virtual screening, we identified the small-molecule modulator Gue1654, which inhibits Gβγ but not Gα signaling triggered upon activation of Gα(i)-βγ by the chemoattractant receptor OXE-R in both recombinant and human primary cells. Gue1654 does not interfere nonspecifically with signaling directly at or downstream of Gβγ. This hitherto unappreciated mechanism of ligand bias at a GPCR highlights both a new paradigm for functional selectivity and a potentially new strategy to develop pathway-specific therapeutics.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22634634 DOI: 10.1038/nchembio.962
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040